Background: Surgery is the fundamental treatment for stage I-IIIA patients. But treatment patterns in different areas of China diverse. In order to deliver high quality care for lung cancer patients, the Chinese National NSCLC outcome registry was founded in 2013, which covers 16 provinces in China. We analyze the data retrieved from this registry. Methods: Data of stage I-IIIa patients were obtained from the NSCLC surgical outcome registry, which included 2040 patients who underwent lung resection surgeries from 20 tertiary hospitals nationwide in 2013. 11 centers which have submitted more than 30 cases in 2013 were included. Stage I-IIIa NSCLC patients from these centers were retrieved. Baseline data, surgical parameters, pathology, number of lymph nodes dissected, and total hospital cost were analyzed. Results: Among the 2040 patients, the mean age was 60.1, while 1297 were male. Mean pre-op forced expiratory volume in 1 second (FEV1) was 2.39 L, FEV1/FVC was 80.1%. 8% patients combined with at least one comorbidity. The average diameter of the tumor was 3.15 cm. Mean operation time was 174 minutes. The post-operative pathology confirmed 62.0% as adenocarcinoma while 31.1% as squamous carcinoma. Based on the data submitted by different centers, 79.5% (mean, 0 to 98.41) patients who were confirmed as stage III patients received adjuvant therapy before surgery. The rate of minimally invasive surgery was 44.9% (mean, 8.1% to 94.7%) in different regions. The number of stations of lymph nodes harvested was 5.8 (mean, 4.3 to 7.4). Mean hospital cost was 55,070 (43,051 to 69,686) RMB.
Background Gastrointestinal Stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract (GIT) i.e. sarcoma. GIST is classified into mutation in KIT (cluster of differentiation 117, CD117) oncogene (85%), Platelet — derived growth factor receptor alpha gene (PDGFRA) (10%) or rarely B-Raf gene. C.Kit - which is mutated & activated in 80% of GIST- is an oncogene which encodes cell surface receptor Tyrosine Kinase TK (CD 117) which is responsible for activation of multiple signaling cascades leading to cellular proliferation. Aim of the Work to explore the best management options of care for patients at Ain Shams University Hospitals (ASUH) by retrospectively analyzing epidemiological factors in Gastrointestinal stromal tumor patients and correlate them to clinical outcome; these factors are either patient or disease ones, while outcome include clinical benefits, survival and encountered toxicities. Patients and Methods this is a retrospective study. This study included 34 patients with GIST treated at the department of Clinical Oncology and Nuclear medicine, Ain Shams University between 2011 -2017 and followed up till 1-2017. Results many prognostic factors were selected for analysis to evaluate their impact on overall survival. Age, gender, site and size of tumor, mitotic index, histopathology, presence of metastasis at time of presentation and anemia all had no statistically significant impact on overall survival. Conclusion the prognosis of GIST is undoubtedly better than other sarcomas. No clear risk factor of GIST. Patient selection is paramount as to minimize the high cost of treatment. Tumor density must be known by Hounsfield unit before treatment to detect pseudo progression. Molecular analysis by PCR is very important to know sensitivity to treatment as a predictive biomarker. Patients should be kept on follow up for early detection of recurrence.
Background & objectives: Presence of TILs in breast cancer indicates better therapeutic responses to neoadjuvant chemotherapy (NAC), increased pCR and improved outcome. We aim at evaluation of TILs in breast cancer biopsies in correlation with pathological response after NAC in locally advanced breast cancer Methods. This study was conducted at Ain Shams university hospital and Maadi Military hospital in Egypt. 45 Female patients with locally advanced breast cancer were treated with NAC; pathological response was assessed. Tumours were categorized into: luminal A, luminal B, Her2 enriched and TNBC. Assessment of TILs (CD4 and CD8 lymphocytes) was based on Immuno-Oncology Biomarker Working Group guidelines. Results: Tumours were classified into high and low TIL groups using the interquartile range cutoff (29%). High CD4 group showed increased pCR (p = 0.003) and smaller residual tumours (p = 0.04). High CD8 group showed a significant association with smaller residual tumours (p = 0.003). At follow-up of 24-months, CD4 and CD8 high groups showed significantly higher 2-years DFS. The difference between CD4 high and low groups was significant in regards to estrogen receptor status, showing higher levels in hormone-negative tumors (p = 0.029). Patients with Her2 subtype showed higher CD4 (p = 0.007) and CD8 expression (p = 0.018). In CD4 & CD8 low groups, more patients developed local recurrence and distant metastasis (p = 0.025). Conclusion: We concluded that TILs may predict response to NAC and overall prognosis of breast cancer. The evaluation of TILs in correlation with mor-How to cite this paper: El-Mahdy, M.M., Ibrahim, R.A., Hamed, R.M., Elkady, M.S., Bayoumy, W.A., Elsayed, Z.M. and Ezz-El-Din, M.M. (2020)
Background Bronchogenic carcinoma is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. This growth can spread beyond the lung by the process of metastasis into nearby tissue or other parts of the body. Most cancers that start in the lung, known as primary lung cancers, are carcinomas, The two main types are small-cell lung carcinoma (SCLC) and non- small-cell lung carcinoma (NSCLC). Aim of the Study Register cases of primary lung tumors presented to Ain shams university hospital during period from June 2018 to June 2019 and to follow up their response to different lines of treatment and to assess delay time between diagnosis and start of treatment. Patients and Methods This study is an observational, analytical and retrospective study, conducted upon 95 cases of primary lung tumor cases presented to Ain Shams University Hospital _oncology chest clinic. Results The main age of our studied population ranging from 17 to 66 years old in cases diagnosed as small cell lung cancer (SCLC), from 30 to 81 years old in cases diagnosed as non small cell lung cancer(NSCLC), eight out of nine cases diagnosed as SCLC were males, sixty six out of 86 NSCLC cases were males, about 66.7% of SCLC cases & 57% of NSCLC were smokers, forty four percent of SCLC presented with performance score 2, while 48.8% of NSCLC presented with performance score 1, Out of 86 cases of non small cell lung cancer 54 were adenocarcinoma, 27 were squamous cell carcinoma, 4 cases were large cell lung cancer and 1 case was mucoepidermoid carcinoma. Dyspnea was the main symptom in SCLC cases (6 cases out of 8). Fibreoptic bronchoscopy was the diagnostic tool in 33.3% of SCLC cases, 29.1% of NSCLC cases. In non small cell lung cancer, US guided biopsy took the second hand after fibreoptic bronchoscopy by 25.6%, Most of cases were stage 4, 77.8% in small cell carcinoma, 80.2% in non small cell lung cancer. SCLC received Gemcitabine/carboplatin in 33.3% of cases, 22.2% of cases received palliative radiotherapy as first line treatment.11.1% of them received definitive radiotherapy as second line treatment.In NSCLC, 25.6% of cases treated with Gemcitabine/carboplatin, 17.4% received palliative radiotherapy.In NSCLC 36% of cases presented with dyspnea then chest pain 22%.The relation between delay time and prognosis as regard disease progression is non significant similar to the relation between delay time from definitive diagnosis to start of treatment)and stage at time of diagnosis. Unlikely, the inverse relation between delay time and ECOG(Eastern Cooperative Oncology Group Performance status) in both small and non small cell lung cancer. Conclusion The relation between delay time and prognosis is non significant similar to the relation between delay time and stage at time of diagnosis. Unlikely, the inverse relation between delay time and ECOG in both small and non small cell lung cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.